Combined high versus low mRNA levels of CYTH2‐ARF6‐AGAP1 provided the most robust 17‐month different in survival of ovarian cancer patients, which occurred in patients with an PI3K‐AKT signature. Here, AKT1 is linked to ovarian carcinoma.